BioAge Labs’ Post

Register below to hear how we discovered our structurally distinct NLRP3 inhibitors at BioAge Labs!

Traditional preclinical efficacy assessments often rely on broad behavioral measures, making it hard to distinguish different mechanisms of action and accurately predict clinical outcomes or side effects. This highlights the need for more sensitive, predictive evaluations. ➡️If you are at the #ECNP2024, check out poster #P1600, presented by 𝗝𝗼𝗻𝗮𝘁𝗵𝗮𝗻 𝗭𝗮𝗽𝗮𝘁𝗮, to learn about Inscopix's circuit-based neurobehavioral assay for 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝘁𝗶𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀.

Autoimmune is HOT 🔥 Cartesian Therapeutics, an mRNA cell therapy biotech, said its lead investigational medicine helped patients with an autoimmune condition that has caught the attention of many biopharmas in recent years.... ...“We believe the positive data presented today demonstrate clinical proof-of-concept of our novel #mRNA #platform and highlight the potential of Descartes-08 to provide deep and durable improvements for patients with MG,” CEO Carsten Brunn said in a press release.... #PIPE #data #clinicaldata #autoimmune #Biopharma #CarT #celltherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #biotech #biotechnology #pharma #pharmact #130million HBM Healthcare Investments AG The Invus Group Schooner Capital Surveyor Capital #TimSpringer #lifescience #lifesciences #myastheniagravis #MG #clinicaltrials

💡 Join HitGen Inc.'s upcoming webinar to discover how DNA-encoded libraries are revolutionizing early-stage, small-molecule drug discovery, especially for targeting G protein-coupled receptors (#GPCRs). 🧬 Learn about the remarkable advancements and impact of #DNAEncodedLibrary in identifying hit compounds for #DrugDevelopment. The expert speakers, Alex Shaginian, PhD, MBA, Rusty Montgomery, and David Israel will cover the unique advantages of DNA-encoded libraries for various targets and provide an overview of different platforms and their applications in drug discovery. BioAge Labs will also share insights from their study on novel indazole #NLRP3 inhibitors, demonstrating the selection strategy and analysis of small molecule structures and activities. ➡️ REGISTER HERE: https://buff.ly/3WeHJCo #SmallMolecule #DrugDevelopment #DrugDiscovery #DrugManufacturing #SmallMoleculeDrug

Join our upcoming Bench Tip webinar that explores the creation and application of 3D cellular models for studying disease pathways and enhancing drug development. Gain insights from the experts on model design, validation, and overcoming various challenges.  #3DCellModels #DrugDevelopment #CellularBiology https://lnkd.in/gcMZD4dd

💡 Join HitGen Inc.'s upcoming webinar to discover how DNA-encoded libraries are revolutionizing early-stage, small-molecule drug discovery, especially for targeting G protein-coupled receptors (#GPCRs). 🧬 Learn about the remarkable advancements and impact of #DNAEncodedLibrary in identifying hit compounds for #DrugDevelopment. The expert speakers, Alex Shaginian, PhD, MBA, Rusty Montgomery and David Israel will cover the unique advantages of DNA-encoded libraries for various targets and provide an overview of different platforms and their applications in drug discovery. BioAge Labs will also share insights from their study on novel indazole #NLRP3 inhibitors, demonstrating the selection strategy and analysis of small molecule structures and activities. ➡️ REGISTER HERE: https://buff.ly/3WeHJCo #SmallMolecule #DrugDevelopment #DrugDiscovery #DrugManufacturing #SmallMoleculeDrug

It was very exciting to participate in this panel discussion at the Main Stage during #SynBioBeta2024 last week in sunny San Jose. Thanks to John Cumbers and his team for putting together another amazing conference; and to Meenakshi Prabhune, PhD for moderating this session on the present and future of Targeted Therapeutics, with insights from peer panelist Mark Kotter, Anil Narasimha and Daniel Georgiev. What an exiciting field #GeneWriting is for unlocking the full potential of #AdvancedTherapies.

📢 We are thrilled to share the publication in OPRD of a new scientific article, "Route Design and Scale-Up of a Topoisomerase I Inhibitor Antibody–Drug Conjugate Payload," this paper results from the fruitful collaboration between William Goundry, Andrew Poulton and Matt Welham from AstraZeneca and Axplora Le Mans' team Bertrand Cottineau, Fanny Magne and Sandrine Ballot.   This publication emphasizes the development and scale-up activities conducted on a new #topoisomerase 1 inhibitor, a major class of ADC payload. It recognizes the expertise of our #ADC center of excellence in developing efficient and robust processes for our clients, benefitting patients with breakthrough therapies. Explore the article ➡ Link in comments   #Highpotency #FriedlanderReaction #RouteDesign #Topoisomerase1Inhibitor

Our latest Spotlight in partnership with ICON plc is here! You can learn more about the different approaches for immunogenicity assessment, including preclinical ADA assessments, singlicate ADA analysis, or complex assay strategies.  Check it out >>> https://hubs.ly/Q02H3lrp0

💡 Join KCAS Bio for a webinar exploring the evolving field of ADA (anti-drug antibody) assays. The featured speakers, Cheikh Kane, PhD and Dominic Warrino will cover the latest strategies for bioanalytical ADA/immunogenicity testing, including the impact of the new lean approach on preclinical and clinical programs. Gain insights from a historical overview of ADA assay concepts over the past decade, future strategies, and relevant case studies. The featured speakers will also discuss current protocols, best practices, and immunogenicity risk assessment. 🔗 REGISTER HERE: https://buff.ly/4dj7tDn #DrugDevelopment #ClinicalResearch #Immunogenicity #MonoclonalAntibodies #AnalyticalTesting #AntibodyDrugConjugate #BioanalyticalTesting #PreClinical #CellGeneTherapies